Equities

InterCure Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
INCR:TLV

InterCure Ltd

Actions
Health CareMedical Equipment and Services
  • Price (ILa)268.00
  • Today's Change0.40 / 0.15%
  • Shares traded43.76k
  • 1 Year change-55.03%
  • Beta1.0915
Data delayed at least 20 minutes, as of Mar 02 2026 15:24 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

InterCure Ltd is an Israel-based company primarily enagged in cannabis industry. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.

  • Revenue in ILS (TTM)355.55m
  • Net income in ILS-61.96m
  • Incorporated1994
  • Employees320.00
  • Location
    InterCure LtdMedinat HaYehudim 85HERZLIYA 4676670IsraelISR
  • Phone+972 732207002
  • Fax+972 97680244
  • Websitehttps://www.intercure.co/
More ▼

Institutional shareholders

1.97%Per cent of shares held by top holders
HolderShares% Held
Healthcare of Ontario Pension Planas of 31 Dec 2025212.50k0.39%
Psagot Mutual Funds Ltd.as of 30 Nov 2025167.56k0.31%
Meitav Mutual Funds Ltd.as of 30 Nov 2025131.68k0.24%
IBI Mutual Funds Management (1978) Ltd.as of 30 Nov 2025127.39k0.23%
AdvisorShares Investments LLCas of 06 Feb 2026104.95k0.19%
Jane Street Capital LLCas of 31 Dec 202576.81k0.14%
KSM Mutual Funds Ltd.as of 30 Nov 202575.72k0.14%
Ayalon Mutual Funds Ltd.as of 30 Nov 202567.34k0.12%
Citadel Securities LLCas of 31 Dec 202566.25k0.12%
Migdal Mutual Funds Ltd.as of 30 Nov 202545.57k0.08%
More ▼
Data from 30 Nov 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.